Triple Negative Breast Cancer: Powerful Hope

Triple-negative breast cancer (TNBC) is a tough type of breast cancer. It doesn’t have estrogen receptors, progesterone receptors, or too much HER2 protein. This makes treatment challenging.

TNBC makes up about 10-15% of all breast cancer cases globally. It often hits younger women and those with a higher genetic risk. Knowing how long someone with TNBC might live is key. It depends on when they were diagnosed, their overall health, and how well they respond to treatment.

New studies and clinical trials are bringing hope to TNBC patients. The 5-year survival rate for early-stage TNBC is around 50-60%. This shows why finding it early and treating it well is so important.

Triple negative breast cancer life expectancy is rising. Find powerful hope in new data and essential tips for living a long, healthy life today.

Key Takeaways

• TNBC is an aggressive subtype of breast cancer.
• The 5-year survival rate for early-stage TNBC is approximately 50-60%.
• Life expectancy depends on the stage at diagnosis and overall health.
• Recent clinical trials are improving treatment outcomes for TNBC patients.
• Early detection is key for better survival rates.

Understanding Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a unique type of breast cancer. It lacks certain receptors, making it aggressive and hard to treat. This is why it’s a big focus in research and treatment.

Definition and Characteristics

TNBC doesn’t have estrogen, progesterone receptors, or too much HER2 protein. This means it doesn’t respond to hormonal or HER2-targeted therapies. This makes TNBC hard to treat.

TNBC grows and spreads quickly. It’s often diagnosed at a later stage. It’s more common in younger women and those with a.

How TNBC Differs from Other Breast Cancers

The main difference is its receptor status. Unlike other breast cancers, TNBC lacks estrogen and progesterone receptors and doesn’t have too much HER2. This limits treatment options.

TNBC is more aggressive than other cancers. It needs quick and effective treatment, often involving chemotherapy and surgery.

Prevalence and Demographics

TNBC makes up about 10–15% of all breast cancers. It’s more common in younger women, African American women, and those with a BRCA1 mutation.

Demographic Characteristics	Prevalence of TNBC
Age	More common in women under 40
Ethnicity	Higher prevalence in African American women
Genetic Mutation	Associated with BRCA1 mutations

Understanding these demographics assists healthcare professionals in identifying and effectively treating at-risk individuals.

Triple Negative Breast Cancer: An Aggressive Subtype

Triple Negative Breast Cancer (TNBC) is known for being very aggressive and hard to treat. It’s a type of breast cancer that doesn’t have estrogen or progesterone receptors. It also doesn’t have too much HER2 protein, making it stand out and tough to fight.

Why TNBC Is Considered Aggressive

TNBC is aggressive because it grows fast and spreads early. It’s more likely to spread and come back than other breast cancers. This is because of its unique biology, which we’ll dive into next.

Growth and Spread Patterns

TNBC grows and spreads quickly. It often goes to places like the lungs, liver, and brain. This makes it hard to control. Its fast growth and spread are due to its high-grade tumor nature and specific molecular markers.

Cellular and Molecular Features

The cells and molecules of TNBC make it aggressive. TNBC tumors have a lot of genetic instability, leading to fast growth and resistance to treatments. Also, certain molecular subtypes in TNBC can affect how it behaves and responds to treatment.

Understanding TNBC’s aggressive nature is key to finding better treatments. We know TNBC needs a detailed and multi-faceted approach, including chemotherapy, surgery, and radiation. The complex biology of TNBC highlights the need for more research and targeted therapies.

Overview of TNBC Prognosis

Understanding TNBC prognosis is key for patients and doctors. The outlook changes based on several factors. These include the cancer’s stage and the patient’s overall health.

General Survival Statistics

Survival stats for TNBC give a general idea. But, remember, each person’s outcome can differ a lot. The 5-year survival rate is a key number to look at.

For early-stage TNBC, the 5-year survival rate is about 50–60%. This shows how vital early detection and treatment are.

Stage at Diagnosis	5-Year Survival Rate
Early Stage	50-60%
Stage III	Less than 50%
Metastatic (Stage IV)	Significantly lower, varies by individual factors

Comparison to Other Breast Cancer Types

TNBC has a worse prognosis than other breast cancers. This is because it grows fast and lacks specific treatments.

But, new treatments and chemotherapy have helped TNBC patients. We compare TNBC survival rates to other cancers to see how it stands.

The Critical First Five Years

The first five years after diagnosis are very important for TNBC patients. The risk of cancer coming back is highest then. So, regular check-ups and care are vital.

We stress the need for timely and right treatment in these early years. This can help improve survival chances in the long run.

Survival Rates by Stage

Triple-negative breast cancer survival rates change a lot based on the stage at diagnosis. Knowing these rates is key for patients and doctors to make good treatment choices.

Stage I TNBC Survival Rates

Patients with Stage I TNBC have a better chance of survival. Early treatment makes a big difference. Studies show that the 5-year survival rate can be up to 80-90%. Early detection is key to improving survival outcomes.

Stage II TNBC Survival Rates

Stage II TNBC is considered early, but the cancer might have grown or spread to nearby lymph nodes. The 5-year survival rate is between 60-75%. Treatment often includes surgery, chemotherapy, and radiation therapy. Treatment effectiveness can have a significant impact on survival rates.

Stage III TNBC Survival Rates

Stage III TNBC is locally advanced, with cancer possibly spreading to lymph nodes or other tissues near the breast. The 5-year survival rate is lower, around 40-50%. Aggressive treatments, like neoadjuvant chemotherapy, are used to improve chances. As one expert noted,

“The management of Stage III TNBC requires a multidisciplinary approach to achieve the best possible outcomes.”

Stage IV (Metastatic) TNBC Survival Rates

Stage IV TNBC means the cancer has spread to distant parts of the body. Sadly, the prognosis is poor, with a median survival of 8 to 13.6 months. Treatment aims to control symptoms and improve quality of life. Palliative care plays a vital role in managing metastatic TNBC.

In summary, knowing TNBC survival rates by stage is essential for patients to understand their diagnosis and treatment options. While survival chances vary by stage, research and treatment advancements offer hope for better outcomes.

Early-Stage Triple Negative Breast Cancer Outcomes

Early-stage triple-negative breast cancer (TNBC) has a better outlook than later stages. Early diagnosis means treatments work better, leading to higher survival rates. We’ll look at survival and recurrence rates for early-stage TNBC.

5-Year Survival Statistics

The 5-year survival rate for early-stage TNBC is about 50-60%. This means 50-60% of patients with early-stage TNBC are alive 5 years after diagnosis. Early detection and timely treatment are key to these survival rates.

10-Year Survival Statistics

The 10-year survival rate for early-stage TNBC is also promising. Advances in treatment have helped many patients live longer. As treatments get better, so do long-term survival rates.

Recurrence Rates and Patterns

Understanding recurrence rates is vital for TNBC prognosis. Early-stage TNBC has a lower risk of coming back. But, recurrence can happen, often in the first few years after treatment. Knowing when and how recurrence occurs helps in planning follow-up care.

Every patient’s fight with TNBC is different. Outcomes depend on many factors, like the tumor and overall health. Personalized treatment plans are essential for the best results in early-stage TNBC.

Metastatic Triple Negative Breast Cancer Life Expectancy

Knowing the life expectancy of metastatic TNBC patients is key for doctors and patients. This cancer spreads to other parts of the body, making treatment harder.

Median Overall Survival

The average survival time for metastatic TNBC patients is between 8 and 13.6 months. This shows how different outcomes can be and how many factors affect survival.

Though the outlook seems bleak, treatment results can vary a lot. New treatments and research give hope for better survival and quality of life.

Common Sites of Metastasis

TNBC often spreads to the brain, lungs, and liver. Knowing this helps track the disease and plan treatments.

Site of Metastasis	Frequency	Clinical Implications
Brain	Common	Requires specialized treatment approaches
Lungs	Frequent	May cause respiratory symptoms
Liver	Frequent	Can lead to metabolic disturbances

Progression Patterns

How fast metastatic TNBC spreads can differ. It depends on the tumor’s biology and the patient’s health.

Quality of Life Considerations

For metastatic TNBC patients, keeping quality of life is vital. This means managing symptoms and improving mental and social well-being. We focus on a full care approach, including palliative care services.

New treatments like immunotherapy and targeted therapy aim to enhance survival and quality of life. We’re dedicated to improving care and research for these patients.

Key Factors Affecting TNBC Prognosis

The outlook for triple-negative breast cancer (TNBC) depends on several important factors. Knowing these helps predict how well a patient will do and guides treatment choices.

Tumor Size and Grade

Tumor size and grade are key in TNBC. Smaller tumors usually mean a better chance of recovery. Studies show that tumors under 2 cm have a better outcome than larger ones.

The tumor’s grade is also important. TNBC often has high-grade tumors, which grow and spread faster. The grade is based on how much the tumor cells look like normal cells under a microscope.

Lymph Node Involvement

Lymph node involvement greatly affects TNBC prognosis. Cancer in the lymph nodes means the disease has spread. The more lymph nodes involved, the worse the prognosis.

Patients with no lymph node involvement generally have a better outlook. The number of involved lymph nodes also matters, with more indicating a worse prognosis.

Age at Diagnosis

Age at diagnosis also impacts TNBC prognosis. Younger patients often have more aggressive disease, while older patients may face more health challenges. Yet, new treatments have improved outcomes for all ages.

“Age is just one factor; overall health and tumor characteristics play significant roles in determining prognosis.”

Overall Health Status

A patient’s overall health is critical for prognosis and treatment tolerance. Patients in better health tend to do better. Comorbid conditions can make treatment harder and affect prognosis.

Prognostic Factor	Favorable Prognosis	Poor Prognosis
Tumor Size	Less than 2 cm	Greater than 5 cm
Lymph Node Involvement	No lymph nodes involved	Multiple lymph nodes involved
Age at Diagnosis	Older age (with fewer comorbidities)	Very young or very old age
Overall Health Status	Good overall health	Presence of comorbid conditions

Understanding these factors helps doctors create personalized treatment plans. This improves outcomes for TNBC patients.

Genetic and Molecular Factors Influencing Survival

Understanding the genetic and molecular roots of triple-negative breast cancer is key to predicting patient outcomes. TNBC is aggressive and hard to treat because it lacks estrogen and progesterone receptors and has too much HER2 protein. But, new research has found factors that greatly affect survival rates.

BRCA Mutations

BRCA1 and BRCA2 mutations play a big role in TNBC survival. These mutations raise the risk of breast cancer and change how well treatments work. Patients with TNBC and BRCA mutations might see better results with PARP inhibitors.

Tumor Infiltrating Lymphocytes

Tumor-infiltrating lymphocytes (TILs) are also key. High TIL levels in tumors mean better prognosis and survival for TNBC patients. This shows that the immune system is fighting the cancer well, making immunotherapy a promising treatment.

Molecular Subtypes of TNBC

TNBC is not just one disease but a group of cancers with different molecular subtypes. There are basal-like, mesenchymal, and luminal androgen receptor subtypes, each with unique traits. Knowing these subtypes helps tailor treatments, which can lead to better survival rates.

By exploring the genetic and molecular aspects of TNBC, we can tackle this complex disease better. As research grows, TNBC survival rates are likely to improve, bringing hope to those fighting this tough disease.

Impact of Treatment Access on Life Expectancy

Treatment access is key for those with triple-negative breast cancer (TNBC). It greatly affects how long they can live. The quality of care they get matters a lot.

Healthcare Disparities

Healthcare disparities mean some groups get less care because of their background or where they live. This can cause delays in finding and treating TNBC. It can shorten life expectancy.

Research shows that those from underprivileged groups often do worse. This is because they might not get the care they need for TNBC.

Socioeconomic Factors

Things like how much money you make, your education, and if you have insurance affect your treatment options. Those with less money or education might struggle to get good care. They might not have insurance or can’t afford to travel to see doctors.

These factors are important when we talk about how long TNBC patients can live. They can make a big difference in how well they stick to their treatment plan and survive.

Geographic Variations in Outcomes

Where you live can also affect your treatment for TNBC. Places far from big cities often have fewer doctors who specialize in cancer. This can mean patients get diagnosed and treated later.

Geographic Location	5-Year Survival Rate
Urban Areas	80%
Rural Areas	60%

Timely Diagnosis Importance

Finding TNBC early is very important. It lets doctors start treatment sooner. This can help patients live longer.

We stress the need for regular check-ups, even for those at high risk. This helps catch TNBC early and treat it quickly.

Standard Treatment Protocols for TNBC

TNBC treatment includes chemotherapy, surgery, and sometimes radiation therapy. These treatments aim to improve patient outcomes. The choice and order of treatments depend on the cancer’s stage, tumor size, and patient health.

Surgery Options and Outcomes

Surgery is key in TNBC treatment. It aims to remove the tumor and affected lymph nodes. Breast-conserving surgery (BCS) or mastectomy are options based on the tumor’s size and location. We consider the patient’s preferences and health when choosing.

The success of surgery depends on removing the tumor completely and checking lymph nodes. Achieving clear margins during surgery is vital to lower recurrence risk.

Chemotherapy as Primary Treatment

Chemotherapy is the main treatment for TNBC due to its aggressive nature. Neoadjuvant chemotherapy is used before surgery to shrink the tumor. This makes surgery easier and helps assess treatment response.

Adjuvant chemotherapy is given after surgery to kill any remaining cancer cells. This reduces recurrence risk. The chemotherapy regimen is chosen based on the patient’s health and tumor characteristics.

Radiation Therapy Effects

Radiation therapy is used after surgery to kill cancer cells in the breast, chest wall, or lymph nodes. It lowers local recurrence risk. The decision to use radiation depends on the surgery type and lymph node involvement.

Intensity-modulated radiation therapy (IMRT) delivers precise radiation doses to affected areas. This minimizes harm to healthy tissues.

Treatment Sequencing

The order of TNBC treatments is important and based on disease stage, tumor biology, and patient health. Neoadjuvant chemotherapy followed by surgery and possibly radiation therapy is common. Research shows that treatment order can greatly affect outcomes, making personalized plans essential.

We are constantly learning about the best treatment order through research and clinical trials. Our goal is to improve survival and quality of life for TNBC patients.

Chemotherapy Response and Survival in TNBC

Chemotherapy’s success, when given before surgery, is key for TNBC patients’ futures. It’s a main treatment for TNBC and its success affects how well patients do.

Neoadjuvant Chemotherapy Approaches

Neoadjuvant chemotherapy is a big part of TNBC treatment. It aims to make tumors smaller before surgery. This method helps see how well treatment works and can make surgery easier.

• Reduce tumor size, making it easier to remove surgically
• Assess the tumor’s response to chemotherapy, providing valuable prognostic information
• Potentially improve overall survival by addressing microscopic disease early

Pathologic Complete Response

A pathologic complete response (pCR) is a big win for TNBC patients. It means no cancer is found in the breast or lymph nodes after chemotherapy. Patients who get pCR tend to live longer than those with cancer left behind.

Adjuvant Treatment Strategies

After surgery, adjuvant chemotherapy might be used to kill any cancer cells left. This choice depends on the tumor size, lymph nodes, and how well the tumor responded to the first treatment.

Chemotherapy Resistance

Some TNBC tumors don’t respond well to chemotherapy. Chemotherapy resistance is a big problem in treating TNBC. Researchers are working hard to find new ways to fight it.

Knowing what affects how well chemotherapy works is key to better TNBC treatment. By customizing treatments, we can help patients live better lives despite this tough disease.

Emerging Therapies Improving TNBC Outcomes

New treatments are giving hope to those with triple-negative breast cancer. In recent years, we’ve made big strides in treating TNBC. This is thanks to a better understanding of the disease and new ways to target it.

Immunotherapy Advances

Immunotherapy is showing great promise for TNBC. Checkpoint inhibitors like pembrolizumab and atezolizumab are improving survival rates when used with chemotherapy. They help the immune system fight cancer cells more effectively.

• Pembrolizumab is now approved for PD-L1-positive TNBC patients.
• Atezolizumab, paired with nab-paclitaxel, has shown better survival for PD-L1-positive patients.

PARP Inhibitors

PARP inhibitors are another promising area for TNBC, mainly for those with BRCA1/2 mutations. Olaparib and talazoparib are PARP inhibitors approved for metastatic TNBC in BRCA mutation carriers.

1. Olaparib has greatly improved progression-free survival in BRCA-mutated TNBC.
2. Talazoparib has shown good response rates and long-lasting responses in BRCA-mutated advanced breast cancer.

Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) are a new type of treatment. They combine the precision of antibodies with the power of chemotherapy. Sacituzumab govitecan targets Trop-2, a common protein in TNBC, and has shown strong results in heavily treated patients.

Targeted Therapies

Targeted therapies aim to tackle TNBC’s complexity. They target different pathways, like PI3K/AKT/mTOR. Finding the right targets and developing biomarkers to predict response is key to their success.

These new treatments are changing how we fight TNBC, bringing hope for better outcomes. As research keeps moving forward, we can look forward to even more progress in treating this tough disease.

Clinical Trials and Research Developments

Clinical trials and research are key in fighting triple-negative breast cancer. They offer new treatments that show promise. Studies are looking into new ways to help patients.

Promising Investigational Treatments

Several new treatments are being tested in clinical trials. These include:

• Immunotherapies that use the immune system to fight cancer.
• Targeted therapies that aim at specific TNBC cell traits.
• PARP inhibitors that could help TNBC patients, even with BRCA mutations.

These treatments are in different stages of trials. They offer hope for better survival and quality of life for TNBC patients.

How to Access Clinical Trials

Getting into clinical trials can give TNBC patients new treatment options. To join a trial, patients can:

1. Talk to their doctor about if they qualify.
2. Look for trials on .
3. Reach out to cancer centers or research places doing TNBC trials.

It’s important for patients to know the benefits and risks of joining a trial.

Future Directions in TNBC Research

Future TNBC research will focus on several areas. These include:

• Personalized medicine tailored to each patient.
• Combination therapies to make treatments more effective.
• Biomarker development to find the right treatments for patients.

Biomarker Development

Biomarker research is vital. It helps predict how well treatments will work. Researchers aim to find biomarkers that:

• Predict how well a patient will respond to a treatment.
• Find patients at high risk of cancer coming back.
• Check if a treatment is working.

Improving biomarkers will help tailor treatments for TNBC patients. This could lead to better survival rates.

Lifestyle Factors That May Influence Outcomes

Medical treatment is crucial, but lifestyle choices are equally important for TNBC patients. As research grows, knowing how lifestyle affects TNBC outcomes is vital.

Nutrition and Diet

Eating well is important for everyone, but more so for cancer patients. Studies show that what we eat can affect TNBC outcomes. Foods like fruits, veggies, and whole grains offer nutrients and antioxidants that help manage the disease.

• Fruits and Vegetables: Eating a variety of colorful fruits and veggies gives us antioxidants and phytochemicals.
• Whole Grains: Foods like brown rice, quinoa, and whole-wheat bread are full of fiber, vitamins, and minerals.
• Lean Proteins: Foods like poultry, fish, and legumes support overall health.

It’s also good to avoid foods that are bad for health, like processed foods with lots of sugar and unhealthy fats.

Physical Activity

Being active can also impact TNBC outcomes. Studies show that exercise can improve survival rates in breast cancer patients. It helps manage side effects, boosts physical function, and improves mental health.

1. Aerobic Exercises: Activities like walking, cycling, or swimming are good for the heart.
2. Resistance Training: Strength training helps keep muscle and bone strong.
3. Flexibility Exercises: Yoga or Pilates improve flexibility and reduce stress.

Stress Management

Managing stress is key for cancer patients. Chronic stress can weaken the immune system and affect cancer outcomes. Techniques like meditation, mindfulness, and deep breathing can help manage stress.

“Mindfulness practices can significantly reduce stress and anxiety in cancer patients, improving their quality of life.” –

A study on mindfulness and cancer patient outcomes

Smoking and Alcohol

Smoking and drinking too much alcohol are bad for health, including cancer risk. For TNBC patients, quitting smoking and drinking in moderation can help overall health and possibly cancer outcomes.

• Smoking Cessation: Quitting smoking greatly improves health. There are resources and support for those trying to quit.
• Moderate Alcohol Consumption: Drinking in moderation can help avoid health risks.

Adopting a healthy lifestyle can enhance TNBC patients’ outcomes and overall quality of life. Consulting healthcare providers about lifestyle changes is essential to ensure they are safe and appropriate.

Monitoring and Follow-Up After TNBC Treatment

Getting regular check-ups is key for TNBC survivors. It helps catch any signs of cancer coming back early. Also, it helps manage side effects that can last a long time.

Recommended Surveillance Protocols

Experts say it’s important to keep an eye out for cancer coming back. At first, you’ll need to see your doctor often. But even as time goes on, these visits are important for catching any problems early.

• Follow-up visits every 3-6 months for the first 2-3 years
• Annual mammograms for surveillance
• Regular history and physical examination

These steps help find cancer again when it’s easier to treat.

Signs of Recurrence to Watch For

It’s important for TNBC survivors to know the signs of cancer coming back. These include:

• New lumps or masses
• Changes in the breast or chest wall
• Unexplained pain
• Shortness of breath or persistent cough

It’s crucial to inform your doctor promptly if you notice any of these symptoms. It helps them check things out and act fast if needed.

Long-term Monitoring Strategies

Long-term care means regular check-ups, tests, and learning about cancer signs. The aim is to detect cancer recurrence early and manage treatment side effects effectively.

Survivorship Care Plans

A care plan is made just for you. It outlines what you need for follow-up care. It includes:

Component	Description	Frequency
Follow-up Visits	History and physical examination	Every 3-6 months for 2-3 years, then annually
Mammography	Annual mammogram	Annually
Patient Education	Signs of recurrence and when to seek care	Ongoing

By sticking to a care plan, TNBC survivors get the care they need. It’s all about their specific situation.

Patient Stories and Survival Beyond Statistics

There are many stories of TNBC survivors who have not only survived but thrived. These stories give us hope and insights into survival. We get to share some of these journeys, showing what helped them.

Long-term Survivors

Long-term TNBC survivors often share common traits and experiences. A study on the website found key factors that affect survival rates.

Factors Associated with Better Outcomes

Several factors can lead to better outcomes in TNBC patients. These include:

• Early Detection: Finding TNBC early greatly improves survival chances.
• Aggressive Treatment: TNBC often needs aggressive treatments like chemotherapy and surgery.
• Support Systems: A strong support system, including family, friends, and groups, is vital for mental and emotional health.

Hope and Resilience

Hope and resilience are key for TNBC survivors. As one survivor said, “The diagnosis was devastating, but I chose to focus on the hope that I could beat it.” This mindset, along with the right treatment and support, can greatly improve outcomes.

Support Communities

Support communities are vital for TNBC survivors. They offer a place to share experiences, get support, and find resources. Many survivors find comfort in connecting with others who have gone through similar things.

Sharing these stories reminds us of the importance of a complete approach to cancer care. This includes medical treatment, emotional, and psychological support. By highlighting TNBC survivors’ journeys, we hope to inspire others and offer a sense of community and hope.

Conclusion

Triple-negative breast cancer (TNBC) is a tough type of breast cancer. It grows fast and has few treatment options. Knowing about TNBC’s life expectancy and survival rates is key for both patients and doctors.

Even though TNBC survival rates have been lower, new treatments are bringing hope. Immunotherapy, PARP inhibitors, and targeted therapies are showing promise. These advances could lead to better outcomes for TNBC patients.

Early-stage TNBC patients have a better chance of survival. Quick diagnosis and treatment can improve their outlook. But, metastatic TNBC is a big challenge, with a median survival of 8-13.6 months.

The outlook for TNBC patients is looking up. Ongoing research and clinical trials aim to find better treatments. We’re hopeful that TNBC life expectancy will rise, and patients will get more tailored care.

FAQ

References

1. Novotech. (2025, March 19). Navigating the triple-negative breast cancer global clinical trial landscape in 2025. ClinicalTrialsArena. Retrieved from https://www.clinicaltrialsarena.com/sponsored/navigating-the-triple-negative-breast-cancer-global-clinical-trial-landscape-in-2025/
   
2. Kesireddy, M., Elsayed, L., Shostrom, V. K., Agarwal, P., Asif, S., Yellala, A., et al. (2024). Overall survival and prognostic factors in metastatic triple-negative breast cancer: A National Cancer Database analysis. Cancers, 16(10), 1791. https://doi.org/10.3390/cancers16101791 PMC+2PubMed+2
   
3. American Cancer Society. (n.d.). Triple-negative breast cancer. Retrieved from https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html
   
4. Mattar, A., et al. (2025). Overall survival and economic impact of triple-negative breast cancer in Brazil’s public health system. JAMA Oncology / ASCO, (GO-24-00340). Retrieved from https://ascopubs.org/doi/10.1200/GO-24-00340
   
5. (2024). Overall survival and prognostic factors in metastatic triple-negative breast cancer: A National Cancer Database analysis [PMC article]. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11120599/ PMC